XTL Accounts Payable from 2010 to 2024

XTLB Stock  USD 1.85  0.03  1.60%   
XTL Biopharmaceutica's Accounts Payable is decreasing over the years with slightly volatile fluctuation. Accounts Payable is expected to dwindle to 950.00. Accounts Payable is the amount XTL Biopharmaceuticals Ltd owes to suppliers or vendors for products or services received but not yet paid for. It represents XTL Biopharmaceutica's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2003-12-31
Previous Quarter
1000
Current Value
223 K
Quarterly Volatility
898.9 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check XTL Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XTL Biopharmaceutica's main balance sheet or income statement drivers, such as Other Operating Expenses of 726.8 K, Research Development of 29.4 K or Total Operating Expenses of 726.8 K, as well as many indicators such as Price To Sales Ratio of 0.15, Dividend Yield of 0.0 or PTB Ratio of 2.41. XTL financial statements analysis is a perfect complement when working with XTL Biopharmaceutica Valuation or Volatility modules.
  
Check out the analysis of XTL Biopharmaceutica Correlation against competitors.

Latest XTL Biopharmaceutica's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of XTL Biopharmaceuticals Ltd over the last few years. An accounting item on the balance sheet that represents XTL Biopharmaceutica obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of XTL Biopharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. XTL Biopharmaceutica's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XTL Biopharmaceutica's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

XTL Accounts Payable Regression Statistics

Arithmetic Mean323,530
Geometric Mean19,272
Coefficient Of Variation238.26
Mean Deviation439,984
Median8,000
Standard Deviation770,836
Sample Variance594.2B
Range3M
R-Value(0.61)
Mean Square Error399B
R-Squared0.38
Significance0.01
Slope(105,758)
Total Sum of Squares8.3T

XTL Accounts Payable History

2024 950.0
2020 2000.0
2019 1000.0
2018 8000.0
2017 4000.0
201615 K
201584 K

About XTL Biopharmaceutica Financial Statements

XTL Biopharmaceutica stakeholders use historical fundamental indicators, such as XTL Biopharmaceutica's Accounts Payable, to determine how well the company is positioned to perform in the future. Although XTL Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in XTL Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on XTL Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in XTL Biopharmaceuticals Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable 1,000.00  950.00 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:
Check out the analysis of XTL Biopharmaceutica Correlation against competitors.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Earnings Share
(0.03)
Return On Assets
(0.14)
Return On Equity
(0.13)
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.